HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $73

Benzinga · 2d ago
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $65 to $73.